Rothwell B, Sheikh K, Knight C, Kamgar F, Jain R, Mamtani R, Kurt M, Poretta T, Broughton E, Teitsson S. Cost-utility of Nivolumab versus observation for the adjuvant treatment of Urothelial Carcinoma (UC) for patients who are at high-risk of recurrence: a United States (US) payer perspective. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun;.